share_log

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Pfizer Inc. (“Pfizer” or the “Reporting Person”)(32.0%)

SEC announcement ·  Mar 20 08:53
Summary by Futu AI
On March 19, 2024, Pfizer Inc. (Pfizer), a leading pharmaceutical company, filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), detailing its ownership stake in Haleon plc. Pfizer reported beneficial ownership of approximately 32% of Haleon's outstanding Ordinary Shares, amounting to 2,955,063,626 shares. This ownership includes both restricted American Depositary Shares (ADSs) and Ordinary Shares held by Pfizer's nominee. The filing was an update to a series of amendments dating back to July 27, 2022, and reflects Pfizer's position prior to a secondary offering and share buyback planned for March 2024. The secondary offering involves the sale of 790,554,820 Ordinary Shares, including both Ordinary Shares and Unrestricted ADSs, with Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, and other underwriters facilitating the transaction. Pfizer has entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. The secondary offering and share buyback are expected to close on March 21, 2024, subject to customary conditions.
On March 19, 2024, Pfizer Inc. (Pfizer), a leading pharmaceutical company, filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), detailing its ownership stake in Haleon plc. Pfizer reported beneficial ownership of approximately 32% of Haleon's outstanding Ordinary Shares, amounting to 2,955,063,626 shares. This ownership includes both restricted American Depositary Shares (ADSs) and Ordinary Shares held by Pfizer's nominee. The filing was an update to a series of amendments dating back to July 27, 2022, and reflects Pfizer's position prior to a secondary offering and share buyback planned for March 2024. The secondary offering involves the sale of 790,554,820 Ordinary Shares, including both Ordinary Shares and Unrestricted ADSs, with Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, and other underwriters facilitating the transaction. Pfizer has entered into a lock-up agreement restricting the sale of additional shares for 90 days post-offering. The secondary offering and share buyback are expected to close on March 21, 2024, subject to customary conditions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.